Drugs / Ad-sig-hMUC-1/ecdCD40L
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02140996 | Sep 2014 → Mar 2017 | carcinoma | Singapore Clinical Research Institute | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad-sig-hMUC-1/ecdCD40L | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02140996 ↗ |
| Known as | Ad-sig-hMUC-1/ecdCD40L vector vaccine | “Therefore the safety and tolerability of the Ad-sig-hMUC-1/ecdCD40L vector vaccine will be tested in this phase I non-randomized open label dose escalation trial for men or...” NCT02140996 ↗ |
| Modality | Vaccine | “this suggests that the Ad-sig-hMUC-1/ecdCD40L vector prime-hMUC-1/ecdCD40L protein boost has the potential to be an effective vaccine in epithelial tumors.” NCT02140996 ↗ |
| Route | Subcutaneous | “two subcutaneous Ad-sig-hMUC-1/ecdCD40L vector injections” NCT02140996 ↗ |